Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:LOXO

Loxo Oncology (LOXO) Stock Price, News & Analysis

Loxo Oncology logo

About Loxo Oncology Stock (NASDAQ:LOXO)

Advanced Chart

Key Stats

Today's Range
$234.66
$234.66
50-Day Range
N/A
52-Week Range
$101.70
$234.93
Volume
400 shs
Average Volume
565,561 shs
Market Capitalization
$7.18 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive LOXO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Loxo Oncology and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LOXO Stock News Headlines

Elon’s BIGGEST warning yet?
Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.tc pixel
See More Headlines

LOXO Stock Analysis - Frequently Asked Questions

Loxo Oncology Inc (NASDAQ:LOXO) posted its quarterly earnings data on Thursday, August, 9th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.15. The biopharmaceutical company earned $42.60 million during the quarter, compared to analyst estimates of $32.36 million. Loxo Oncology had a negative trailing twelve-month return on equity of 16.42% and a negative net margin of 43.49%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Loxo Oncology investors own include Meta Platforms (META), Bristol Myers Squibb (BMY), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), GW Pharmaceuticals (GWPH) and Micron Technology (MU).

Company Calendar

Last Earnings
8/09/2018
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LOXO
CIK
1581720
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($5.31)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$148.87 million
Net Margins
-43.49%
Pretax Margin
N/A
Return on Equity
-16.42%
Return on Assets
-8.66%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.62
Quick Ratio
3.62

Sales & Book Value

Annual Sales
$21.30 million
Price / Sales
337.23
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$12.63 per share
Price / Book
18.58

Miscellaneous

Outstanding Shares
30,610,000
Free Float
N/A
Market Cap
$7.18 billion
Optionable
Optionable
Beta
2.51
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:LOXO) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners